Immunogeniciteit, veiligheid en verdraagbaarheid van RF1V-1018-vaccin bij volwassenen 18 tot 55 jaar oud
Fase 2, gerandomiseerde, multicenteronderzoek naar de immunogeniteit, veiligheid en verdraagbaarheid van RF1V-1018-vaccin bij volwassenen 18 tot 55 jaar oud
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Studie Overzicht
Toestand
Gedetailleerde beschrijving
This dose-finding study will evaluate the immunogenicity, safety, and tolerability of multiple doses and regimens of rF1V-1018 vaccine in healthy adults. Immunogenicity blood samples will be drawn at several timepoints during the study. Participants will return to the clinic for periodic visits for study specific evaluations including evaluation of immunogenicity and safety. Safety assessments will be done at regular intervals through the end of the trial.
Six dose regimens will be tested in Part 1 of the study. Up to two dose regimens from Part 1 will be chosen for Part 2 of the study.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33172
- 103
-
-
Kansas
-
El Dorado, Kansas, Verenigde Staten, 67042
- AMR- El Dorado
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 889119
- AMR- Las Vegas
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45212
- CTI Clinical Research Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Adults 18 to 55 years of age
- Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
- Able to comply with the protocol schedule and procedures
- Able and willing to provide written informed consent
- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection
A premenopausal woman who has at least one of the following is considered not of childbearing potential:
- Documented hysterectomy
- Documented bilateral salpingectomy
- Documented bilateral oophorectomy
- Documented and current bilateral tubal ligation or occlusion
Exclusion Criteria:
-
A history of plague disease or have previously received any plague vaccine
-
Active tuberculosis or other systemic infectious process
-
History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
-
History of autoimmune disorder
-
History of sensitivity to any component of trial vaccines
-
Body mass index ≥ 30 kg/m2
-
Has received the following prior to any trial injection:
a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any live vaccine ii) Any investigational medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed.
ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
-
If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
-
Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
-
Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
-
History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD)
-
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1 Arm 1
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Experimenteel: Part 1 Arm 2
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Experimenteel: Part 1 Arm 5
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Experimenteel: Part 1 Arm 6
|
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Experimenteel: Part 1 and Part 2: Arm 3
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
|
Experimenteel: Part 1 and Part 2: Arm 4
This Part 1 arm was selected for Part 2. |
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Regimen 5 Regimen 6 |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Anti-RF1V antilichaamniveau
Tijdsspanne: 4 weken na het laatste studievaccin
|
4 weken na het laatste studievaccin
|
|
|
Evaluate safety of rF1V-1018
Tijdsspanne: injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
Evaluate adverse events |
injection reactions through 7 days after each study vaccine, adverse events for 28 days after each study vaccine; SAEs, MAEs, imAESIs through 6 months after the final study vaccine
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- DV2-DC02-02
- VCG26632 (Andere identificatie: Sanofi)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .